Anti-tumor therapeutic effects in mice treated with Listeria monocytogenes (Lm)-LLO immunotherapy in combination with PD-L1

被引：0
|
作者：
Molli, Poonam [1 ]
Wallecha, Anu [1 ]
机构：
[1] Advaxis Inc, Princeton, NJ USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2513
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
    Mkrtichyan, Mikayel
    Chong, Namju
    Abu Eid, Rasha
    Wallecha, Anu
    Singh, Reshma
    Rothman, John
    Khleif, Samir N.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2013, 1
  • [2] A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice
    Pan, Jiayi
    Zeng, Wuyi
    Jia, Jiangtao
    Shi, Yi
    Wang, Danni
    Dong, Jun
    Fang, Zixuan
    He, Jiashan
    Yang, Xinyu
    Zhang, Rong
    He, Menghua
    Huang, Maoping
    Fu, Bishi
    Zhong, Bei
    Liu, Hui
    VACCINES, 2022, 10 (07)
  • [3] Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
    Zhang, Weinan
    He, Zhiqiang
    Liang, Fucheng
    Gong, Jie
    Tan, Liuchang
    Yang, Juan
    Song, Siji
    Xie, Luoyingzi
    Lu, Yuangang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (18) : 16763 - 16778
  • [4] Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
    Weinan Zhang
    Zhiqiang He
    Fucheng Liang
    Jie Gong
    Liuchang Tan
    Juan Yang
    Siji Song
    Luoyingzi Xie
    Yuangang Lu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16763 - 16778
  • [5] Pharmacokinetic analysis of anti-PD-1 and PD-L1 antibodies and evaluation of their anti-tumor effects
    Hatakeyama, Hiroto
    Kurino, Taiki
    Matsuda, Reiko
    Suzuki, Hiroyuki
    Terui, Ayu
    Uehara, Tomoya
    Arano, Yasushi
    Hisaka, Akihiro
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells
    Park, Ji-Eun
    Keam, Bhumsuk
    Park, Ha-ram
    Kim, Soyeon
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV
    Zhang, C.
    Wu, S.
    Xue, X.
    Li, M.
    Qin, X.
    Li, W.
    Han, W.
    Zhang, Y.
    CYTOTHERAPY, 2008, 10 (07) : 711 - 719
  • [8] Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
    Garces, Alvaro H. Ingles
    Au, Lewis
    Mason, Robert
    Thomas, Jennifer
    Larkin, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 695 - 708
  • [9] Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
    Munoz, Luis Enrique
    Huang, Lei
    Bommireddy, Ramireddy
    Sharma, Richa
    Monterroza, Lenore
    Guin, Rohini N.
    Samaranayake, Sarah G.
    Pack, Christopher D.
    Ramachandiran, Sampath
    Reddy, Shaker J. C.
    Shanmugam, Mala
    Selvaraj, Periasamy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [10] A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
    Kong, Xianbin
    Lu, Peng
    Liu, Chuanxin
    Guo, Yuzhu
    Yang, Yuying
    Peng, Yingying
    Wang, Fangyuan
    Bo, Zhichao
    Dou, Xiaoxin
    Shi, Haoyang
    Meng, Jingyan
    MOLECULAR MEDICINE REPORTS, 2021, 23 (05)
12345